Drug intelligence / Profile preview

MK-1697

Development stage: Discontinued
Lead developer: Merck
Administration: Intravenous

Overview

MK-1697 is a biological drug candidate developed by Merck Sharp & Dohme for the treatment of advanced solid tumors, including colorectal cancer and head and neck squamous cell carcinoma. It functions as an inhibitor of LAG3 (lymphocyte activation gene 3 protein), a checkpoint protein involved in immune regulation. By inhibiting LAG3, MK-1697 was intended to enhance anti-tumor immune responses. The drug was administered intravenously and classified as a large molecule/biological product. Clinical development reached phase 1 before being discontinued[1][2][3].

Targets

LAG3 (Lymphocyte activation Gene-3 protein)

Beyond the preview

Go deeper on MK-1697.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-1697.

Explore the full profile